AEGiS-AIDSWeekly: HIV/AIDS: Data on HIV/AIDS reported by researchers at University of Amsterdam

Important note: Information in this article was accurate in January 2008. The state of the art may have changed since the publication date.

HIV/AIDS: Data on HIV/AIDS reported by researchers at University of Amsterdam

AIDSWEEKLY Plus; Monday, January 1, 2008
Staff Medical Writers

NewsRx -- In this recent study, researchers in Netherlands conducted a study "To objectively assess changes in body fat distribution in a subgroup of antiretroviral therapy-naive participants in a randomized comparative trial of regimens including a nucleoside analogue backbone of didanosine with either lamivudine or stavudine (see also HIV/AIDS). Whole body dual-energy X-ray absorptiometry (DEXA) scans were performed at baseline and weeks 48 and 96 of therapy in all 19 patients from one of the sites participating in the Antiretroviral Regimen Evaluation Study (ARES)."

"Patients had been randomized to receive nelfinavir/didanosine/stavudine (n = 8), nevirapine/didanosine/lamivudine (n = 7), or ritonavir-boosted saquinavir/didanosine/lamivudine (n = 4). In an intent-to-treat analysis, patients allocated to didanosine plus stavudine-containing treatment after 96 weeks had lost a median of 1,825 g (-26%) of total limb fat, as compared to a median gain of 1,639 (48%) and 403 (6%) g in those randomized to the didanosine/lamivudine plus nevirapine or saquinavir-containing regimens, respectively. These changes in limb fat were statistically significantly different when comparing patients allocated to stavudinecontaining treatment with both of the other two treatment arms combined (P =.01)," wrote S.H. Lowe and colleagues, University of Amsterdam.

The researchers concluded: "This study suggests that didanosine/lamivudine, when combined with either nevirapine or ritonavir-boosted saquinavir over 96 weeks of therapy, is possibly not associated with limb fat atrophy, in contrast to when treatment contained didanosine, stavudine, and nelfinavir combined."

Lowe and colleagues published their study in HIV Clinical Trials (Stavuldine but not Didanosine as part of HAART contributes to peripheral lipoatrophy: A substudy from the Antiretroviral regimen evaluation study (ARES). HIV Clin Trials. 2007 Sep-Oct;8(5):337-44.

For additional information, contact S.H. Lowe, University of Amsterdam, IATEC, Academy Med Center, Pietersbergweg 9, NL-1105 BM Amsterdam, Netherlands.

Publisher contact information for the journal HIV Clinical Trials is: Thomas Land Publishers, Inc., 255 Jefferson Rd., St. Louis, MO 63119, USA.

Keywords: Netherlands, HIV/AIDS, AIDS, Acquired Immunodeficiency Syndrome, Anti-Infectives, Antivirals, Clinical Trial Research, Didanosine, Drugs, HAART, HIV, Human Immunodeficiency Virus, Lamivudine, Nelfinavir, Nevirapine, Nonnucleoside Reverse Transcriptase Inhibitor, Nucleoside Analog, Nucleoside Reverse Transcriptase Inhibitor, Pharmaceuticals, Protease Inhibitor, Ritonavir, Saquinavir, Stavudine, Therapy, Treatment, Virology, University of Amsterdam.

This article was prepared by AIDS Weekly editors from staff and other reports.

2008-01-07
AW080101

Copyright © 2008 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.